FGF13 and metastatic malignant neoplasm: Together with our finding of a positive correlation between high FGF13 expression and cloperastine sensitivity, we anticipate that highly metastatic cancer cells expressing high levels of FGF13 can be selectively killed with cloperastine and other H1 receptor antagonists, providing a new approach to treating metastatic cancers.